Spotlight On... Shortage of docs to deploy stents for stroke leads to a dilemma; MiMedx gets FDA OK for export; Migraine prevention device has better compliance than drugs; and more...

The sudden demand for mechanical stent thromobectomy devices to treat stroke had led to a shortage of neurointerventionists to deploy the devices during the associated procedure. Some interventional cardiologists want to get involved, but many neurointerventionists don't think it's appropriate, leading to a "turf war." "I think it's something cardiologists should embrace, not because we need to take over other people's domains but because we're in the perfect position," said Dr. David Hildick-Smith, an interventional cardiologist at Royal Sussex Brighton Hospital in Brighton, England. But Dr. Philip Meyers, a neurointerventionalist at Columbia University Medical Center said, "Stroke procedures really ought to be performed at comprehensive stroke centers where patients have access to the full range of stroke services, because there's so much more to the treatment of stroke than a procedure alone." More

@FierceMedDev: KKR, Panasonic form newco Ascensia from Bayer Diabetes buy for $1.1B. Article | Follow @FierceMedDev

@EmilyWFierce: Drug price increases saw 'high water mark' year in 2015: Analysts. FiercePharma story | Follow @EmilyWFierce

@VarunSaxena2: NEA partner outlines challenging med tech VC landscape heading into 2016. Article | Follow @VarunSaxena2

> The FDA has certified MiMedx ($MDGX) sheet form allografts, which enables the company to market them ex-U.S. More

> Data on almost 15,000 patients who got the Cefaly Technology trigeminal nerve stimulation between March 2014 and October 2015 to prevent migraines found a compliance rate of more than 72% with the device. That's twice that typically reported for oral migraine prevention medicines. More

> GreatCall has launched the first wearable to connect activity tracking to a nationwide mobile safety service for the elderly. More

Biotech News

@FierceBiotech: The scoop on every new drug approved in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: It's all happening so fast--Alector raises $29M; NextCure launches with $67M; Pfizer leads $15M round for Cortexyme. More | Follow @JohnCFierce

@DamianFierce: Tweeting from HATEFUL 8 intermission & have to say it was jarring when Bruce Dern turned to the camera and said "The 8 of us sure are h8ful." | Follow @DamianFierce

> FDA gets into Rhythm with a 'breakthrough' title for orphan obesity drug. Story

> Allergan spends $90M to get its hands on a topical Botox project. Article

> Another Chinese biopharma lines up for a billion-dollar IPO. Item

Pharma News

@FiercePharma: China's Jiangsu Hansoh plans $3B IPO to tap investor demand. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: MannKind resolves to find new Afrezza marketing deal after Sanofi bails on partnership. FiercePharmaMarketing story | Follow @CarlyHFierce

> If hospitalized Valeant chief makes an exit, it'll be without a parachute. Article

> Drug price increases saw 'high water mark' year in 2015: Analysts. Report

CRO News

> PPD spins out its in-house biotech as sale rumors swirl. More

> Charles River spends $585M on WIL Research amid a buyout spree. Article

> UCB taps Evotec to pitch in on drug discovery. Story

> Altasciences rebrands its web of CROs in hopes of standing out. Report

Pharma Manufacturing News

> Baxter recalls more of its saline solutions after a bug was found. Report

> PharMEDium recalls blood pressure control drug due to discoloration/degradation. More

> French developer TxCell signs Belgian CMO for manufacturing deal. Story

> GSK Australia plant to begin using blow-fill-seal technology for vaccines. Item

> Hospira recalls magnesium sulfate injectable due to bad barcoding. Article

Pharma Asia News

> China's Simcere seeks return to public market with $1B HKEx IPO. Story

> Chinese New Year alert in Hong Kong after bird flu fatality. News

> Wanda plans $2.3B hospital investment in China. More

> Precision medicine plan in China may be announced in March. Report

> Takeda bets on microbiome targets in GI push with Enterome deal. Article

Suggested Articles

BD will begin offering a point-of-care COVID-19 antibody assay, which operates like a combination of a blood glucose test and a home pregnancy test.

Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for large-scale production.

NantWorks’ ImmunityBio has begun a supercomputing collaboration with Microsoft to map out the spike protein of the novel coronavirus.